SCHEMBL332255

SCHEMBL332255

CC(Cc1ccc(-c2ccccc2)cc1)OC=O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SRR Q9GZT4 2/20 0.47
PSAT1 Q9Y617 2/20 0.47
PPARG P37231 8/20 0.46
PPARA Q07869 6/20 0.46
MME P08473 4/20 0.45
ACE P12821 4/20 0.45
CPA1 P15085 2/20 0.45
ACE2 Q9BYF1 2/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
ACP3 P15309 1/20 0.44
ACACB O00763 1/20 0.43
FFAR1 O14842 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3678022 0.88 TAAR1 (0.55) MEN1KMT2ATAAR1CYP1A2CYP2D6
SCHEMBL8698887 0.83 MME (0.46) SRRPSAT1PPARGPPARAMME
SCHEMBL7312539 0.81 PPARG (0.41) PPARGPPARAMEN1KMT2ATAAR1
SCHEMBL10590311 0.81 MEN1 (0.41) PPARGPPARAMEN1KMT2ATAAR1
SCHEMBL159574 0.79 TP53 (0.58) SRRPSAT1PPARGPPARAMME
SCHEMBL16021181 0.79 PPARG (0.42) PPARGPPARAMEN1KMT2ATAAR1
SCHEMBL8283176 0.79 TP53 (0.58) SRRPSAT1PPARGPPARAMME
SCHEMBL27760849 0.77 SRR (0.41) SRRPSAT1PPARGPPARAMME
SCHEMBL332254 0.76 SRR (0.46) SRRPSAT1PPARGPPARAMME
SCHEMBL1335887 0.76 TAAR1 (0.50) SRRPSAT1MMEACECPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 637 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114585615-A Synthesis of 6-methyl-N1- (4- (pyridin-3-yl) pyrimidin-2-yl) benzene-1, 3-diamine 新加坡艺思高艾斯特生物科技有限公司 2022-06-03 CN claimed
CN-108218903-B Process for the preparation of L-BPA 南京中硼联康医疗科技有限公司 2020-12-08 CN claimed
CN-111770928-A Synthesis of oligonucleotides and nucleic acids 埃万奈蒂克有限公司 2020-10-13 CN claimed
CN-108373479-B Process for the preparation of L-BPA 南京中硼联康医疗科技有限公司 2020-06-12 CN claimed
US-9822146-B2 Process for the manufacture of degarelix and its intermediates FERRING B.V. (NL) 2017-11-21 US claimed
US-20160145301-A1 PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES FERRING BV (NL) 2016-05-26 US claimed
EP-2161277-B1 Asymmetric synthesis of peptides UNIV READING (GB) 2013-04-10 EP claimed
US-8399612-B2 Asymmetric synthesis of peptides UNIVERSITY OF READING (GB) 2013-03-19 US claimed
US-20120190816-A9 ASYMMETRIC SYNTHESIS OF PEPTIDES UNIVERSITY OF READING 2012-07-26 US claimed
EP-2081919-B1 TETRAHYDROFURO [3, 2-B]PYRR0L-3-0NE INTERMEDIATES AMURA THERAPEUTICS LTD (GB) 2012-05-23 EP claimed
EP-1660465-A2 PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES Rib-X Pharmaceuticals, Inc. (US) 2006-05-31 EP claimed
EP-1644401-A1 IMPROVED PROCESS FOR SUPPORTED PHASE SYNTHESIS UCB, S.A. (BE) 2006-04-12 EP claimed
US-6958330-B1 Polycyclic α-amino-ε-caprolactams and related compounds ELAN PHARMACEUTICALS, INC. (US) 2005-10-25 US claimed
WO-2005012271-A2 PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES RIB-X PHARMACEUTICALS, INC. (US) 2005-02-10 WO claimed
WO-2005005457-A1 IMPROVED PROCESS FOR SUPPORTED PHASE SYNTHESIS UCB, S.A. (BE) 2005-01-20 WO claimed
WO-2004013139-A2 PROCESS FOR PREPARING 7-AZAINDOLES EISAI CO., LTD (JP) 2004-02-12 WO claimed
EP-0376218-B1 Racemization free attachment of amino acids to solid phase PERSEPTIVE BIOSYSTEMS INC (US) 1999-02-24 EP claimed
US-5187270-A Solid phase synthesis of peptides using the reaction product of an N-protected amino acid and a 2,4-dichlorophenyl (4-halo methylphenoxy)acetate; efficiency; purity; kinetics MILLIPORE CORPORATION (US) 1993-02-16 US claimed
EP-0376218-A2 Racemization free attachment of amino acids to solid phase PERSEPTIVE BIOSYSTEMS, INC. (US) 1990-07-04 EP claimed
US-3944590-A ALKYL PHENYL CARBONATES CIBA-GEIGY CORPORATION (US) 1976-03-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145301-A1 PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES VIP, HABP2, DPP9 SRR 1740/4885PSAT1 3757/4885PPARG 4643/4885
US-20120190816-A9 ASYMMETRIC SYNTHESIS OF PEPTIDES PTMS, NGLY1, QPCT SRR 32/4885PSAT1 1115/4885PPARG 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.